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Influence of muscle mass in the assessment of lower limb 
strength in COPD: Validation of the Prediction Equation 
 
 
 
Introduction: 
 
Measurement of lower limb muscle strength is valuable in the clinical management of 
patients with Chronic Obstructive Pulmonary Disease (COPD). Muscle weakness is 
common, independently relates to mortality and morbidity, and is modifiable by exercise 
rehabilitation and potentially anabolic drug therapy1-4. Assessment of lower limb strength can 
be easily and reproducibly performed in clinical settings through Quadriceps Maximal 
Voluntary Contraction (QMVC) measurement. Establishment of reference ranges in healthy 
adults is required to identify weakness to assist decisions regarding therapies and assess 
outcomes in both clinical and research settings1, 5. Prediction equations previously used to 
study strength in COPD populations have included fat-free mass (FFM) thereby 
incorporating a measure of muscle mass. The inclusion of FFM may underestimate the 
prevalence of muscle weakness, particularly in populations where muscle mass is frequently 
low, as in COPD2. We aimed to examine the influence of muscle mass measurement on 
prediction equations for QMVC by determining the prevalence of weakness in two separate 
COPD cohorts using prediction equations with and without fat-free mass derived from 
healthy subjects.  
 
Methods 
Prediction equations were derived using multiple linear regression from an existing cohort of 
healthy adults (HC). Age, gender, weight and height were entered in the first model. A 
whole-body measure of FFM was added for the second. The derived equations were used to 
calculate individual percent predicted (%pred) values of QMVC in two COPD cohorts; one 
recruited from primary care (COPD-PC) and the other from a complex COPD outpatient 
clinic (COPD-CC). The lower limit of normal was used as a threshold for the presence of 
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weakness. A further description of the participants, measurements and analysis is provided 
in the supplementary material.  
 
Results: 
175 HC participants were included and 301 patients with COPD (n=112 COPD-PC, n= 189 
COPD-CC). Baseline characteristics can be found in the supplementary material (Table S1).   
 
Prediction Models Derived from Healthy Subjects: 
 
Model without FFM (FFM-): 
QMVC= (-0.318xA) + (13.138xG) + (0.245xW) + (29.781xH) - 18.072 
QMVC (kg), A:age(yrs) G:gender: (F=0), W:weight: (kg), H:Height (m) 
R: 0.773, R2: 0.598, SEE: 8.86 p≤0.005  
 
Model including FFM (FFM+): 
QMVC = (-0.320xA) + (10.670xG) + (0.566xFFM) + 20.952 
FFM: fat-free mass (kg) 
R: 0.770, R2: 0.585, SEE: 8.90 p≤0.005 
 
Application of the prediction equations in patients with COPD 
The predicted values for QMVC using the FFM- and the FFM+ model in the two COPD 
cohorts were calculated. Individual measured values were then compared to respective 
predictions as percentages to yield the percent predicted value (%pred) for both models in 
all cohorts, presented in Table 1. 
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Table 1: QMVC values expressed as percent predicted values and number 
classed as weak using the FFM- and FFM+ models for the COPD cohorts 
 
  
 Primary Care COPD 
n=112 
 
Complex Care COPD 
n=189 
FFM- Model  
%pred QMVC: 
 
88.3 (23.6) 54.0 (16.4) 
Number classed as weak (%): 
 
 
17 (15.2%) 101 (53.4%) 
FFM+ Model 
%pred QMVC: 
 
88.8 (22.4) 59.2 (17.8) 
Number classed as weak (%): 13 (11.6%) 78 (41.3%) 
 
 
  
Mean values and SD of measured Quadriceps Maximal Voluntary Contraction (QMVC) presented as 
a percentage of the values predicted (%pred) and the number in each cohort classed as weak using 
the FFM- and FFM+ models. 
Abbreviations: FFM+: Fat-free mass model, FFM- model without fat-free mass, SD: standard 
deviation, n: number in each group. 
 
 
QMVC Weakness: 
The number and proportion of each cohort classified as weak is presented in Table 1.  
The FFM- model increased the percentage defined as weak (3.6% increase in COPD-PC 
and 11.9% in COPD-CC) compared to the FFM+ model. 
 
The distribution of the Standardised Residuals calculated using the FFM- and FFM+ 
equations for the HC, Primary Care and Complex Care COPD cohorts in relation to the 
threshold of weakness are shown in Figure 1.  
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Discussion: 
We present two prediction equations for QMVC that estimate the presence of lower limb 
muscle weakness, one including and one without muscle mass (estimated using whole body 
measures of FFM). In healthy adults, inclusion of FFM did not affect explained variance of 
the prediction. However, when applied to COPD cohorts there was a difference in the 
assessment of weakness between the two equations, which was amplified in those with 
more severe disease.  
 
Whilst percentage predicted values were similar in the Primary Care COPD (COPD-PC) 
cohort using both equations there was a marginally greater number classed as weak with the 
FFM- model. A larger difference occurred between models in the Complex Care Cohort 
(COPD-CC). Using the FFM+ model %pred values were higher and fewer were assigned as 
weak (Table 1 and Figure 1). This results from the partial adjustment for the lower muscle 
mass associated with more severe disease by the inclusion of FFM in the prediction 
equation. Where muscle mass is not abnormally low within the COPD-CC the difference in 
the classification of weakness between the models is reduced (details of this sub-analysis 
are supplied in the supplementary material). 
 
The prevalence and magnitude of muscle weakness observed and the finding that this 
occurred in milder disease (managed in primary care) but was more pronounced in those 
with more severe COPD is consistent with other reports2, 4, 6. Previous reference equations 
for QMVC have variably included muscle mass2, 4. A negligible difference in predictions with 
the inclusion of muscle mass in healthy subjects was reported in an examination of isokinetic 
muscle strength7. A comparison of different reference equations for muscle strength in 
patients with COPD, one including FFM, demonstrated differences between them8. We 
advance previous studies by directly comparing how model components influence 
predictions by using the same healthy cohort to derive equations and applying them to 
separate COPD cohorts of differing severities, from different healthcare sectors. We have 
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identified statistical thresholds of “normality” for muscle strength both in absolute terms and 
relative to an individual’s muscle mass. The prediction does not encompass regional 
differences in muscle mass that might be important in some patients with COPD and clearly 
has relevance to the prediction of QMVC, a measure of regional muscle function. The impact 
of the identification of muscle weakness using this method on treatment stratification (e.g. for 
local muscle reconditioning or whole body anabolic therapies) requires further investigation. 
 
We acknowledge some limitations. Different methods were used to measure FFM in the two 
COPD cohorts, which could affect the predicted values but would have minimal effect on 
comparison of the prediction models9.  The functional and prognostic relevance of the 
identified lower limit of normal for muscle strength requires confirmation through linkage with 
outcomes such as functional status and mortality.  
 
Proximal lower limb muscle dysfunction has significant implications for mortality, morbidity 
and healthcare utilisation in COPD4. Measurement is important in clinical assessment with 
the potential to aid targeting of therapeutic interventions such as strength training, nutritional 
support and anabolic drug therapy, availability of accessible reference values for 
interpretation will assist implementation1, 10.  
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Supplementary Material 
 
Participants 
The Healthy adult control (HC) group and the COPD-PC were participants in the Physical 
Activity and Respiratory Health (PhARaoH) Study in which healthy adults were recruited 
through community advertisement and patients with COPD through primary care clinics 
located in Leicestershire, UK1. The following inclusion criteria for the HC group were used for 
analysis; FEV1> 80% predicted, FEV1/FVC ratio >0.7, mMRC <2, age ≤40. Patients were 
included if they had a physician diagnosis of COPD that was confirmed by spirometric 
testing at baseline using established guidelines2. 
The COPD-CC was recruited from a Leicestershire based hospital complex COPD service 
designed for patients with advanced COPD. Referrals were from General Practitioners and 
other respiratory specialists as previously described3. The two studies from which 
participants for this study are drawn had relevant ethical approval (13-EM-0389, 
13/EM/0287).  
 
Measurements 
In all three groups height was measured using a stadiometer to the nearest 0.01 metre (m) 
and weight using digital weighing scales to the nearest kilogram (kg). Body Mass Index 
(BMI(kg/m2)) was then derived from these measures (weight(kg)/height(m)2). In the HC 
group and the COPD-PC body composition was measured using Bio-electrical impedance 
analysis (BIA) (Tanita MC780MA). Body composition was measured by Dual energy x-ray 
absorptiometry (DEXA) (LUNAR DEXA scanner) in the COPD-CC. Fat-free mass (FFM) was 
then calculated using the established method of the sum of lean mass and bone mineral 
content4. All participants underwent spirometry and measurements are expressed as a 
percentage of reference values5. 
 
 
QMVC measurement 
The methodology for QMVC measurement was consistent across the cohorts6. 
Measurements were performed with participants seated, knees bent at a 90° angle, with the 
torso secured with adjustable belts. The dynamometer was attached to the lower leg just 
above the level of the malleoli ensuring a straight vector. Participants were encouraged to 
push out the lower leg and exert maximal effort for six seconds. The best reading from the 
dominant leg following at least 3 attempts was recorded (in kg).   
 
Statistical Analysis 
The prediction equations were derived within the HC group using multiple linear regression 
with bootstrapping of 1000 samples. Forced entry method was used for the model without 
fat-free mass (FFM-). Age, gender, weight and height were entered initially as they are 
theoretically implicated and previous relationships have been found7, 8. A hierarchical 
approach was then used for the second model (FFM+) with fat-free mass entered first 
followed by age and gender and then weight and height. This order was chosen to prioritise 
the inclusion of fat-free mass. Only variables that reached significance (p≤0.05) were 
retained in the models. Weight and height were removed from the second model due to 
collinearity and non-significance. The distribution of residual values was assessed for 
normality and models checked for absence of multicollinearity and heteroscedasticity. There 
was one extreme outlier (>3 standard deviations above mean QMVC) which skewed the 
distribution of the residuals so was removed from further analyses. The linearity of 
relationships was also assessed and established. Only complete cases were entered in the 
analyses.  
 
The prediction equations were used to classify weakness in each of the cohorts using a 
threshold of the lower limit of normal (LLN) corresponding to the threshold above which 95% 
of the healthy cohort lie. This equates to a standardised residual below -1.645 using the 
prediction equations and the standard error of the estimate (SEE) for the healthy cohort. The 
standardised residual for an individual was calculated as: 
 
(Measured QMVC-Predicted QMVC)/standard error of the estimate (SEE)* 
*SEE from HC 
 
Participants with QMVC values below this would therefore be classified as having 
quadriceps weakness.  
 
A sub-analysis was performed to calculate the percent predictions and the number classified as 
weak for each model in those within the COPD-CC without a low fat-free mass index 
(FFM/height2)10. The results of this are shown in Table S2. 
 
Differences in baseline characteristics between the HC and COPD cohorts, and between the 
standardised residuals of the models within the cohorts, were analysed using independent t-
tests, or Mann-Whitney U tests if parametric assumptions were not met. All analyses were 
performed using SPSS (version 22). The TRIPOD checklist for developing prediction models 
was used to check the methodology and reporting9. 
 
 
 
 
 
 
 
 
 
 
Table S1: Baseline characteristics of the Healthy Control, Primary Care COPD and 
Complex Care COPD cohorts  
 
 
 HC 
 
 
Primary Care COPD 
 
Complex Care COPD 
 
n 175 112 189 
Age (yrs) 54 (14) 68 (9)* 66 (12)† 
BMI(kg/m2) 25.8 (6.3) 27.4 (6.4) 24.7 (9.5)† 
FFM (kg) 47.7 (14.9) 58.1 (17.6)* 45.4 (14.6)† 
QMVC (kg) 32.0 (18) 33.0 (16.8) 17.1 (8.4)† 
FEV1 
(%predicted) 
102.0 (20) 66.1 (24.8)* 29.0 (16)† 
Gender M=55(31.4%) M=74(66.1%)* M=108(57.1%)† 
    
Displayed as median and Interquartile Range (IQR) unless stated.  
Abbreviations: n: number of subjects, HC: Healthy Control, IQR: interquartile range, BMI: body mass 
index, FFM: fat-free mass, QMVC: quadriceps maximal voluntary contraction, FEV1: forced expiratory 
volume in 1 second, M: male. *Statistical difference between Healthy Control Group and Primary Care 
COPD group (P<0.05) †Statistical difference between Healthy Control Group and Complex Care 
COPD group (P<0.05). 
 
Table S2: QMVC values expressed as percent predicted values and number classed 
as weak using the FFM- and FFM+ models in COPD-CC without low Fat-free Mass 
Index 
 
  
n 56 
 
FFM- Model  
%pred QMVC: 
 
60.4 (16.8) 
Number classed as weak (%): 
 
 
22 (35.5%) 
FFM+ Model 
%pred QMVC: 
 
66.7 (18.5) 
Number classed as weak (%): 19 (30.6%) 
 
 
 
Mean values and SD of measured Quadriceps Maximal Voluntary Contraction (QMVC) presented as 
a percentage of the values predicted (%pred) and the number classed as weak using the FFM- and 
FFM+ models. 
Abbreviations: FFM+: Fat-free mass model, FFM- model without fat-free mass, SD: standard 
deviation, n: number in COPD-CC without low fat-free mass index. 
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